Intravitreal anti-VEGF
Used to treat diabetic macular oedema and, in selected cases, proliferative diabetic retinopathy.
Diabetes can affect every layer of the eye, but the most consequential complication is what happens to the small blood vessels of the retina. Diabetic retinopathy and diabetic macular oedema can develop with no symptoms at all until vision is already affected — and an annual screening visit is what catches them while there is still time.
Early diabetic eye disease often goes undetected because it may cause no warning signs.
By the time symptoms appear, the disease may already be advanced.
Dark spots or floaters drifting across sight
A sudden change in vision, blur, or new floaters
Trouble seeing at night or in low light
Colours appearing faded or washed out
Early diabetic retinopathy often develops without symptoms because central vision remains unaffected. Regular screening can detect subtle retinal changes before symptoms appear, allowing closer monitoring and timely treatment when needed.
The right approach depends on the type and stage of retinal disease. Some patients need regular monitoring without immediate treatment. Others develop diabetic macular oedema or proliferative diabetic retinopathy and may require prompt treatment. Depending on the findings, options may include intravitreal anti-VEGF injections, retinal laser photocoagulation or vitrectomy surgery for advanced disease.
Used to treat diabetic macular oedema and, in selected cases, proliferative diabetic retinopathy.
Used to treat proliferative diabetic retinopathy and reduce the risk of severe vision loss.
In advanced cases, vitrectomy can remove blood and scar tissue that are affecting the retina and vision.
Dr. JD Ferwerda, MD: Dutch-trained ophthalmologist specialising in cataracts, lens exchange, retinal disease, glaucoma, and AMD.